Sarcoma Unit, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany.
Sarcoma Unit, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany,
Oncol Res Treat. 2020;43(11):613-619. doi: 10.1159/000509519. Epub 2020 Aug 27.
The objective of this study was to investigate the prognosis of patients with metastatic soft tissue sarcomas (STS) and to define prognostic indicators for overall survival (OS).
All patients who were treated at the Sarcoma Unit at the Mannheim University Medical Center between 2010 and 2016 and who developed metastatic disease deriving from a STS were included in this retrospective analysis. OS was investigated using data from clinical records and German registry offices. Clinical and pathological characteristics were recorded and analyzed.
A total number of 212 patients developed metastatic disease from STS during that period. Median OS after first documentation of metastatic disease was 24 months (95% CI 21-33). 1-, 2-, and 5-year OS rates were 70.0% (95% CI 64-77), 49.9% (95% CI 43-58), and 24.8% (95% CI 19-33), respectively. In multivariate analysis, significant predictors for mortality appeared to be gender, age, location and size of the primary tumor, histology, and disease-free interval.
Being treated in a high-volume STS reference center in Germany, patients with metastatic disease could demonstrate an increased OS compared to former analyses. These data can be used as a benchmark for upcoming studies and highlight that further research on treatment strategies in this rare disease is urgently needed.
本研究旨在探讨转移性软组织肉瘤（STS）患者的预后，并确定总生存期（OS）的预后指标。
本回顾性分析纳入了 2010 年至 2016 年期间在曼海姆大学医学中心肉瘤科治疗且发生转移性疾病的 STS 患者。OS 采用临床记录和德国登记处的数据进行研究。记录和分析了临床和病理特征。
在此期间，共有 212 例患者发生 STS 转移性疾病。首次记录转移性疾病后的中位 OS 为 24 个月（95%CI 21-33）。1、2 和 5 年 OS 率分别为 70.0%（95%CI 64-77）、49.9%（95%CI 43-58）和 24.8%（95%CI 19-33）。多变量分析显示，性别、年龄、原发肿瘤的位置和大小、组织学和无病间期是死亡的显著预测因素。
在德国的一个高容量 STS 参考中心接受治疗，转移性疾病患者的 OS 可能比以前的分析有所提高。这些数据可用作未来研究的基准，并强调迫切需要对这种罕见疾病的治疗策略进行进一步研究。
